[Liver Transplantation for Treating Hepatocellular Carcinoma].
Xiang-de Liu,Zhan-yu Yang,Shu-guang Wang,Ping Bie,Shu-guo Zheng,Lei-da Zhang,Yu He,Qian Lu,Zhi-qing Yang,Jia-hong Dong
DOI: https://doi.org/10.3760/j.issn:1007-3418.2006.04.005
2006-01-01
Abstract:OBJECTIVE:To evaluate the role of orthotopic liver transplantation (OLT) in treating hepatocellular carcinoma (HCC).METHODS:Data of 92 consecutive orthotopic liver transplantations (OLTs) performed during January 1999 and February 2005 at our institution were analyzed.RESULTS:Of the 92 recipients, 8 HCC patients were stage I, 13 were stage II, 12 stage III and 59 stage IV (UICC TNM staging system). Overall 1-, 2-, 3-, 5-year patient survival rates were 65.3%, 27.0%, 20.0%, and 6.9%, respectively. When OLT indications were considered, best recipients survival was obtained in stage I patients (100.0%, 100.0%, 66.7%, and 50.0% at 1, 2, 3, and 5 years, respectively) and stage II patients (85.7%, 66.7%, and 66.7% at 1, 2 and 3 years, respectively). Whereas, 1, 2, 3 and 5-year recipients survival rates were 50.0%, 0, 0, 0 in stage III patients, and 58.1%, 20.0%, 13.0% and 5.0% in stage IV patients.CONCLUSIONS:The prognosis of different stages of HCC patients who underwent OLT was significantly different. The OLT recipients with HCC should be strictly selected. Long-term recipient survival could be obtained in stage I and stage II patients.